Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

31.06
-1.0800-3.36%
Pre-market: 31.490.4300+1.38%04:13 EDT
Volume:1.30M
Turnover:41.80M
Market Cap:2.87B
PE:-4.94
High:34.15
Open:32.95
Low:30.15
Close:32.14
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

GlobeNewswire
·
06 Jan

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga
·
03 Jan

Ultragenyx Pharma Price Target Maintained With a $95.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Dec 2024

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)

TIPRANKS
·
24 Dec 2024

BRIEF-Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
20 Dec 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
20 Dec 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
20 Dec 2024

Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
20 Dec 2024

Ultragenyx Pharma Is Maintained at Overweight by Wells Fargo

Dow Jones
·
20 Dec 2024

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

GlobeNewswire
·
20 Dec 2024

Ultragenyx Reports Patient Dosing in Angelman Syndrome Trial

MT Newswires Live
·
19 Dec 2024

BRIEF-Ultragenyx Announces First Patient Dosed In Pivotal Phase 3 Aspire Study Evaluating Gtx-102 In Angelman Syndrome

Reuters
·
19 Dec 2024

Ultragenyx Pharmaceutical Inc - Primary Endpoint Is Improvement in Cognition Assessed by Bayley-4

THOMSON REUTERS
·
19 Dec 2024

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating Gtx-102 in Angelman Syndrome

THOMSON REUTERS
·
19 Dec 2024

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

GlobeNewswire
·
19 Dec 2024

Ultragenyx Seeks FDA Accelerated Approval for Gene Therapy to Treat Sanfilippo Syndrome

MT Newswires Live
·
19 Dec 2024

Ultragenyx submits BLA to FDA for UX111

TIPRANKS
·
19 Dec 2024

Ultragenyx Submits Biologics License Application to the U.S. FDA for Ux111 Aav Gene Therapy for the Treatment of Sanfilippo Syndrome Type a (Mps Iiia)

THOMSON REUTERS
·
19 Dec 2024

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewswire
·
19 Dec 2024

U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart

Reuters
·
17 Dec 2024

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."